TOPAZ-1 Dosing Schedule for Durvalumab, Gemcitabine, and Cisplatin
The TOPAZ-1 regimen consists of durvalumab 1500 mg IV on day 1, gemcitabine 1000 mg/m² IV on days 1 and 8, and cisplatin 25 mg/m² IV on days 1 and 8, administered every 3 weeks for up to 8 cycles, followed by durvalumab 1500 mg IV monotherapy every 4 weeks until disease progression. 1, 2
Induction Phase (Cycles 1-8)
Each 21-day cycle includes:
- Durvalumab: 1500 mg IV infusion on Day 1 only
- Gemcitabine: 1000 mg/m² IV over 30 minutes on Days 1 and 8
- Cisplatin: 25 mg/m² IV on Days 1 and 8 (administered after gemcitabine)
Continue this combination for a maximum of 8 cycles (24 weeks total). 3, 1
Maintenance Phase (After Cycle 8)
Following completion of chemotherapy:
- Durvalumab monotherapy: 1500 mg IV every 4 weeks (28-day cycles)
- Continue until disease progression, unacceptable toxicity, or other discontinuation criteria 3, 1
Critical Considerations for a 79-Year-Old Patient
Renal Function Assessment
For cisplatin eligibility, calculate creatinine clearance (CrCl):
- CrCl ≥30 mL/min: Proceed with standard cisplatin dosing
- CrCl <30 mL/min or borderline renal function: Consider oxaliplatin substitution 4, 5
The TOPAZ-1 trial specifically used cisplatin 25 mg/m² on days 1 and 8, which is a fractionated, lower-intensity schedule compared to traditional cisplatin 75-100 mg/m² every 3 weeks. This fractionated approach reduces nephrotoxicity risk while maintaining efficacy. 1
Oxaliplatin Substitution (If Needed)
If cisplatin is contraindicated due to renal impairment:
- Oxaliplatin: 130 mg/m² IV on Day 1 only (not days 1 and 8)
- Combine with gemcitabine 1000 mg/m² on days 1 and 8
- This creates a modified "GEMOX" backbone with durvalumab 4, 6
Important caveat: The TOPAZ-1 trial did not include oxaliplatin substitution, so this represents extrapolation from biliary tract cancer guidelines showing gemcitabine-oxaliplatin activity. The survival benefit with durvalumab may differ from the proven TOPAZ-1 regimen. 4, 7, 5
Dose Modifications for Myelosuppression
On Day 1 of each cycle:
- Hold treatment if ANC <1,500/µL or platelets <100,000/µL
- Resume when counts recover 8
On Day 8 of each cycle (gemcitabine/cisplatin only):
- ANC ≥1,200 AND platelets ≥75,000: Give 100% dose
- ANC 1,000-1,199 OR platelets 50,000-75,000: Give 75% dose
- ANC 700-999 AND platelets ≥50,000: Give 50% dose
- ANC <700 OR platelets <50,000: Hold Day 8 doses 8
Durvalumab dosing does not require adjustment for hematologic toxicity—only hold if severe immune-related adverse events occur. 3
Monitoring Requirements
Before each cycle:
- Complete blood count with differential
- Comprehensive metabolic panel (renal and hepatic function)
- Thyroid function tests (baseline and periodically)
- Assessment for immune-related adverse events 3
Imaging:
- CT chest/abdomen/pelvis every 6-9 weeks to assess response per RECIST 1.1 criteria 1
Key Safety Considerations
Permanently discontinue durvalumab for:
- Grade 3-4 immune-related pneumonitis
- Grade 4 immune-related hepatitis or AST/ALT >8x ULN
- Grade 3-4 immune-related colitis
- Any life-threatening immune-related adverse event 3
Common toxicities in TOPAZ-1:
- Neutropenia (21% grade 3-4)
- Anemia (19% grade 3-4)
- Thrombocytopenia (less common than with traditional cisplatin schedules)
- Immune-related adverse events occurred in 2.4% (grade 3-4) 1, 9
Age-Specific Considerations
At 79 years old, this patient falls within the TOPAZ-1 study population (age range 18-96 years). Pharmacokinetic studies show no clinically significant differences in durvalumab clearance based on age. 3 However, monitor closely for:
- Cumulative cisplatin nephrotoxicity
- Myelosuppression (may be more pronounced in elderly)
- Immune-related adverse events (no age-related increase in incidence)
The fractionated cisplatin schedule (25 mg/m² days 1 and 8) used in TOPAZ-1 is better tolerated than traditional high-dose cisplatin, making it more appropriate for older patients. 1, 2